Literature DB >> 22120973

Mass spectrometry analyses of κ and λ fractions result in increased number of complementarity-determining region identifications.

Ingrid Broodman1, Dominique de Costa, Christoph Stingl, Lennard J M Dekker, Martijn M VanDuijn, Jan Lindemans, Rob J van Klaveren, Theo M Luider.   

Abstract

Sera from lung cancer patients contain antibodies against tumor-associated antigens. Specific amino acid sequences of the complementarity-determining regions (CDRs) in the antigen-binding fragment (Fab) of these antibodies have potential as lung cancer biomarkers. Detection and identification of CDRs by mass spectrometry can significantly be improved by reduction of the complexity of the immunoglobulin molecule. Our aim was to molecular dissect IgG into κ and λ fragments to reduce the complexity and thereby identify substantially more CDRs than by just total Fab isolation. We purified Fab, Fab-κ, Fab-λ, κ and λ light chains from serum from 10 stage I lung adenocarcinoma patients and 10 matched controls from the current and former smokers. After purification, the immunoglobulin fragments were enzymatically digested and measured by high-resolution mass spectrometry. Finally, we compared the number of CDRs identified in these immunoglobulin fragments with that in the Fab fragments. Twice as many CDRs were identified when Fab-κ, Fab-λ, κ and λ (3330) were combined than in the Fab fraction (1663) alone. The number of CDRs and κ:λ ratio was statistically similar in both cases and controls. Molecular dissection of IgG identifies significantly more CDRs, which increases the likelihood of finding lung cancer-related CDR sequences.
Copyright © 2012 WILEY-VCH Verlag GmbH & Co. KGaA, Weinheim.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 22120973     DOI: 10.1002/pmic.201100244

Source DB:  PubMed          Journal:  Proteomics        ISSN: 1615-9853            Impact factor:   3.984


  5 in total

Review 1.  A perspective toward mass spectrometry-based de novo sequencing of endogenous antibodies.

Authors:  Sebastiaan C de Graaf; Max Hoek; Sem Tamara; Albert J R Heck
Journal:  MAbs       Date:  2022 Jan-Dec       Impact factor: 6.440

2.  Novel Antibody-Peptide Binding Assay Indicates Presence of Immunoglobulins against EGFR Phospho-Site S1166 in High-Grade Glioma.

Authors:  Lona Zeneyedpour; Christoph Stingl; Johan M Kros; Peter A E Sillevis Smitt; Theo M Luider
Journal:  Int J Mol Sci       Date:  2022-05-02       Impact factor: 6.208

3.  Cerebrospinal-fluid-derived immunoglobulin G of different multiple sclerosis patients shares mutated sequences in complementarity determining regions.

Authors:  Vaibhav Singh; Marcel P Stoop; Christoph Stingl; Ronald L Luitwieler; Lennard J Dekker; Martijn M van Duijn; Karim L Kreft; Theo M Luider; Rogier Q Hintzen
Journal:  Mol Cell Proteomics       Date:  2013-08-22       Impact factor: 5.911

4.  Synthetic Polyclonal-Derived CDR Peptides as an Innovative Strategy in Glaucoma Therapy.

Authors:  Carsten Schmelter; Kristian Nzogang Fomo; Natarajan Perumal; Caroline Manicam; Katharina Bell; Norbert Pfeiffer; Franz H Grus
Journal:  J Clin Med       Date:  2019-08-15       Impact factor: 4.241

5.  Method development of immunoglobulin G purification from micro-volumes of human serum for untargeted and targeted proteomics-based antibody repertoire studies.

Authors:  Yu-Ting Chang; Ming-Chu Chang; Yun-Jung Tsai; Christine Ferng; Hsi-Chang Shih; Ya-Po Kuo; Chung-Hsuan Chen; I-Lin Tsai
Journal:  J Food Drug Anal       Date:  2018-10-27       Impact factor: 6.157

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.